25 suspended. 25 Phase 2, 4 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 25 | Suspended 25 |
| Phase 1 | 4 | Suspended 4 |
| Phase 3 | 2 | Suspended 2 |
Follow Mental Disorders: new trials by email Literature Review of Mental Disorders trials Research Report on Mental Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Department of Defense PTSD Adaptive Platform Trial - Intervention D - SLS-002 Intervention D SLS-002, Intervention D Placebo - Post Traumatic Stress Disorder | Phase 2 | Suspended | Global Coalition for Adaptive Research | 200 | 2028-05-01 | 2026-05-20 |
| The Dose Finding Study of DAOIB Added to tDCS for AD DAOIB - Transcranial Direct Current Stimulation, Dementia | Phase 2 | Suspended | Chang Gung Memorial Hospital | 140 | 2027-01-01 | 2026-03-20 |
| Mild-Intensity Whole Body Hyperthermia (WBH) for Major Depressive Disorder Tocilizumab, Placebo, Whole-Body Hyperthermia - Major Depressive Disorder | Phase 2 | Suspended | Massachusetts General Hospital | 35 | 2026-12-01 | 2025-11-13 |
| Repeated Administration of Cannabis Varying in THC and CBD Cannabis - Cannabis | Phase 2 | Suspended | New York State Psychiatric Institute | 100 | 2026-10-01 | 2026-09-01 |
| Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV Pramipexole ER, Escitalopram - Major Depressive Disorder, Mild Neurocognitive Disorder | Phase 2 | Suspended | National Institute of Allergy and Infectious Diseases (NIAID) | 186 | 2026-05-17 | 2026-07-14 |
| Department of Defense PTSD Adaptive Platform Trial - Master Protocol Intervention A Fluoxetine Hydrochloride (HCl), Intervention A Placebo, Intervention B Vilazodone Hydrochloride (HCl) - Post Traumatic Stress Disorder | Phase 2 | Suspended | Global Coalition for Adaptive Research | 800 | 2023-11-02 | 2026-06-30 |
| Department of Defense PTSD Adaptive Platform Trial - Intervention A - Fluoxetine Intervention A Fluoxetine Hydrochloride (HCl), Intervention A Placebo - Post Traumatic Stress Disorder | Phase 2 | Suspended | Global Coalition for Adaptive Research | 200 | 2023-11-02 | 2026-05-20 |
| Department of Defense PTSD Adaptive Platform Trial - Intervention C - Daridorexant Intervention C Daridorexant, Intervention C Placebo - Post Traumatic Stress Disorder | Phase 2 | Suspended | Global Coalition for Adaptive Research | 200 | 2023-11-02 | 2026-06-30 |
| An Investigation of Psilocybin on Behavioural and Cognitive Symptoms of Adults With Fragile X Syndrome Psilocybin, 1.5 mg - Fragile X Syndrome, Behavior | Phase 2 | Suspended | Nova Mentis Life Science Corp | 10 | 2023-03-28 | 2024-05-08 |
| Dose-Ranging Trial of Inhaled Cannabis for Acute Migraine Treatment THC ~2.5%, THC ~5%, THC ~10% - Migraine, Cannabis | Phase 2 | Suspended | University of California, San Diego | 20 | 2023-02-15 | 2026-03-16 |
| D-serine AudRem: R33 Phase D-serine, Placebo - Schizophrenia, Schizo Affective Disorder | Phase 1 / Phase 2 | Suspended | New York State Psychiatric Institute | 60 | 2022-12-01 | 2026-04-29 |
| Accelerated TMS in Psychosis repetitive Transcranial Magnetic Stimulation (rTMS) - Schizophrenia, Schizoaffective Disorder | Phase 1 / Phase 2 | Suspended | Beth Israel Deaconess Medical Center | 20 | 2022-11-29 | 2026-04-22 |
| A Proof of Concept, Phase 2, Double-blind, Randomized Trial With d-Methadone Product Versus Placebo D-methadone, Placebo - Restless Legs Syndrome | Phase 2 | Suspended | Mauro Manconi | 50 | 2022-10-22 | 2026-03-13 |
| Treating Nightmares in Posttraumatic Stress Disorder With Clonidine and Doxazosin Clonidine, Doxazosin, Placebo - Posttraumatic Stress Disorder | Phase 2 | Suspended | Charite University, Berlin, Germany | 53 | 2022-06-17 | 2025-08-13 |
| Impact of Repeatedly-Administered THC-cannabis on Experimental Pain and Abuse Liability in Humans Active Cannabis, Placebo Cannabis - Cannabis, Pain | Phase 2 | Suspended | New York State Psychiatric Institute | 16 | 2021-08-01 | 2026-09-24 |
| Pregabalin Trial for the Treatment of Alcohol Use Disorder Pregabalin, Placebo - Alcohol Use Disorder | Phase 2 | Suspended | New York State Psychiatric Institute | 50 | 2021-01-11 | 2025-02-14 |
| CBD Oil for Reducing Emotional Impact of COVID-19 CBD Isolate, Full Spectrum CBD Oil, Broad-Spectrum CBD Oil - Anxiety Depression, Alcohol Abuse | Phase 2 / Phase 3 | Suspended | University of Texas at Austin | 200 | 2020-12-04 | 2023-11-22 |
| Clinical Intervention on Cognitive Impairment of Schizophrenia With Metabolic Syndrome Omega-3 polyunsaturated fatty acids, Xbox aerobic exercise, transcranial direct current stimulation,tDCS - Schizophrenia | Phase 2 | Suspended | Shanghai Mental Health Center | 120 | 2020-10-01 | 2023-04-18 |
| Use of CBD Oil in the Treatment of Posttraumatic Stress Disorder CBD Isolate, CBD Broad Spectrum, Placebo oil - Post Traumatic Stress Disorder | Phase 2 | Suspended | University of Texas at Austin | 150 | 2020-01-15 | 2023-11-22 |
| Intranasal Ketamine With Dexmedetomidine for the Treatment of Children With Autism Spectrum Disorder ketamine and dexmedetomidine, ketamine, Saline - Autism Spectrum Disorder | Phase 2 | Suspended | Guangzhou Women and Children's Medical Center | 50 | 2018-01-20 | 2022-04-12 |
Showing 20 of 25. Sign in to see all of them.
Stress Disorders, Post-Traumatic (6) · Schizophrenia (4) · Cognitive Dysfunction (3) · Marijuana Abuse (3) · Alcoholism (2) · Depressive Disorder, Major (2) · Psychotic Disorders (2) · Autism Spectrum Disorder (1) · Behavior (1) · Breast Neoplasms (1) · COVID-19 (1) · Color Vision Defects (1) · Delirium (1) · Dementia (1) · Depression (1)
Nervous System Diseases (9) · Pathological Conditions, Signs and Symptoms (6) · Signs and Symptoms (6) · Stress Disorders, Traumatic (6) · Trauma and Stressor Related Disorders (6) · Chemically-Induced Disorders (5) · Neurocognitive Disorders (4) · Neurologic Manifestations (4) · Schizophrenia Spectrum and Other Psychotic Disorders (4) · Substance-Related Disorders (4) · Cognition Disorders (3) · Alcohol-Related Disorders (2) · Behavior (2) · Brain Diseases (2)
Ketamine (2) · Sodium Chloride (2) · nabiximols (2) · Bromocriptine (1) · Clonidine (1) · Cognitive Training (1) · D-methadone (1) · Dexmedetomidine (1) · Docosahexaenoic Acids (1) · Dopamine (1) · Doxazosin (1) · Dronabinol (1) · Ephedrine (1) · Epinephrine (1) · Escitalopram (1)
Global Coalition for Adaptive Research (4) · New York State Psychiatric Institute (4) · University of Texas at Austin (2) · Beth Israel Deaconess Medical Center (1) · Chang Gung Memorial Hospital (1) · Charite University, Berlin, Germany (1) · CoMentis (1) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (1) · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico (1) · Guangzhou Women and Children's Medical Center (1) · Massachusetts General Hospital (1) · Mauro Manconi (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Nova Mentis Life Science Corp (1) · Shanghai Mental Health Center (1)
United States (18) · China (2) · Italy (2) · Botswana (1) · Brazil (1) · Canada (1) · Germany (1) · India (1) · Kenya (1) · Malawi (1) · Mexico (1) · Peru (1) · Philippines (1) · South Africa (1) · Switzerland (1)
Michael J Telch, Ph.D. (2) · Alessandro Santini, MD (1) · Antonio Pesenti, MD (1) · David Crowley, MD (1) · David P Walling, PhD (1) · Hyman Muss, MD (1) · Luciano Gattinoni, MD, FRCP (1) · Marie Wood, MD (1) · Mark H. Lewis (1) · Marvin Hausman, MD (1) · Mauro Manconi, Prof. MD (1) · Michael Quintel, MD, PhD (1) · Nancy K Sweitzer, MD, PhD (1) · Nathaniel M Schuster, MD (1) · Qing Zhao, Doctor (1)
PMID 30243062, PMID 36154908, PMID 40764082
R21AA028371 (1), R21DA050752 (1)